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Abstract
The need for public-private partnerships arose against the backdrop of inadequacies on the part of
the public sector to provide public good on their own, in an efficient and effective manner, owing
to lack of resources and management issues. These considerations led to the evolution of a range
of interface arrangements that brought together organizations with the mandate to offer public
good on one hand, and those that could facilitate this goal though the provision of resources,
technical expertise or outreach, on the other. The former category includes of governments and
intergovernmental agencies and the latter, the non-profit and for-profit private sector. Though such
partnerships create a powerful mechanism for addressing difficult problems by leveraging on the
strengths of different partners, they also package complex ethical and process-related challenges.
The complex transnational nature of some of these partnership arrangements necessitates that
they be guided by a set of global principles and norms. Participation of international agencies
warrants that they be set within a comprehensive policy and operational framework within the
organizational mandate and involvement of countries requires legislative authorization, within the
framework of which, procedural and process related guidelines need to be developed. This paper
outlines key ethical and procedural issues inherent to different types of public-private arrangements
and issues a Global Call to Action.
Public-private partnerships in health – a global 
call to action
Public-private partnerships are being increasingly encour-
aged as part of the comprehensive development frame-
work. The need to foster such arrangements is supported
by a clear understanding of the public sectors inability to
provide public goods entirely on their own, in an efficient,
effective and equitable manner because of lack of
resources and management issues. These considerations
have necessitated the development of different interface
arrangements, which involve the interfacing of organiza-
tions that have the mandate to offer public good on one
hand, and those that could facilitate this goal.
Within the health sector, public-private partnerships are
also the subject of intensely fueled debate [1]. Several
examples, which fall within this framework, highlight a
potential for the creation of a powerful mechanism for
addressing difficult problems by leveraging on the
strengths of different partners; however, these also illus-
trate complex issues, as such arrangements bring together
a variety of players with different and sometimes
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conflicting interests and objectives, working within differ-
ent governance structures [2].
This paper focuses on public-private partnerships that are
intended to address broad questions of providing sustain-
able health outcomes rather than on the day-to-day inter-
action that occurs when the government buys a health
service from a private supplier or where it leaves the entire
matter of health service supply to the private sector.
The public sector in this paper refers to national, provin-
cial/state and district governments; municipal administra-
tors, local government institutions, all other government
and inter-governmental agencies with the mandate of
delivering 'public goods'. The word private denotes two
sets of structures; the for-profit private encompassing com-
mercial enterprises of any size and the non-profit private
referring to Non Governmental Organizations (NGOs),
philanthropies and other not-for-profits. The word part-
nership in this paper refers to long term, task oriented, and
formal relationships. There has been ample critique relat-
ing to the convention of using the word partnership to
describe such arrangements; much of this debate is valid,
given that there are certain requisites for coining such an
association. For the same reasons it also needs to be differ-
entiated from privatization, which involves permanent
transfer of control through transfer of ownership right or
an arrangement in which the pubic sector shareholder has
waived its right to subscribe. A distinction also needs to be
made between partnerships and contractual arrangements,
particularly with regard to the relationship between the
public sector and NGOs. Although such arrangements can
be used for strategic purposes, they are inherently distinct
from partnerships.
Types of public-private interface arrangements
the database of the Initiative on Public-Private Partnerships
for Health of the Global Forum for Health Research lists 91
international partnership arrangements in the health sec-
tor, which can qualify to be called public-private partner-
ships. Of these, 76 are dedicated to infectious disease
prevention and control, notably AIDS, tuberculosis and
malaria; four focus on reproductive health issues, three on
nutritional deficiencies whereas a minority focus on other
issues (health policy and research {1}, injection and
chemical safety {2}, digital divide {1}, blindness and cat-
aract {4})[3]. This categorization takes into account large
transnational public-private partnerships. There are, how-
ever, many other arrangements at a country level, which
bring in their wake similar challenges as the ones posed by
larger partnerships.
Several classifications have been proposed to conceptual-
ize and categorize public-private partnerships. These may
be based on the terms of the constituent membership or
the nature of activity [4,5]. However by virtue of the defi-
nitions and the characteristics of the public and private sec-
tors, it can be stated that public-private arrangements are
fostered either when governments and inter-governmen-
tal agencies interface with the for-profit private sector to tap
into resources, or the non-profit private sector for technical
expertise or outreach. Several varieties of arrangements of
various sizes, forms and scope at a global, regional or
country level qualify to fall within this categorization.
Transnational partnerships involving a visible role of the
for-profit sector are at one end of the spectrum. These usu-
ally involve larger partnerships and a complex grouping;
depending upon their structure, they may bring together
several governments, local and international NGOs,
research institutions and UN agencies in transnational
programs, often also involving the non-profit sector. Such
partnerships can be housed and coordinated by different
sources [6]. They can be owned by the pubic sector and
have private sector participants such as in the case of Glo-
bal Alliance for Vaccines and Immunization (GAVI) [7],
Roll Back Malaria (RBM) [8], Stop TB partnership (Stop
TB) [9], Safe Injections Global Network (SIGN) [10], Glo-
bal Polio Eradication Programme (PEI) [11], the Special
Programme for Research and Training in Tropical Dis-
eases (TDR) [12], and the Special Programme for Research
Development and Research Training in Human Repro-
duction (HRP) [13]. Partnerships can be principally
orchestrated by companies such as in the case of Action TB
[14], and can be legally independent such as the Interna-
tional Aids Vaccine Initiative (IAVI) [15], Medicines for
Malaria Venture (MMV) [16], Global Alliance for TB Drug
Development (GATBDD) [17], and the Concept Founda-
tion (CF) [18]. Large partnerships can also be hosted by a
civil society NGO; examples include the Malaria Vaccine
Initiative (MVI) [19], the Mectizan Donation Programme
(MDP) [20], and the HIV Vaccine Initiative (HVI) [21].
At the other end of the spectrum, there are examples of
individual governments forming partnerships with the
for-profit private sector [22]. There are also examples of
situations when a government partners with an NGO with
a particular technical strength, technical or outreach
related. The recent evolution of a public-private partner-
ship for the prevention and control of non-communica-
ble diseases in Pakistan is an example of this approach,
where the government leverages on the technical strength
of the private sector partner for addressing an emerging
health challenge [23]. Examples also exist of NGOs seek-
ing support from corporate partners both at a national
and an international level. The World Heart Federation
has recently structured transparent and successful busi-
ness relationships with the corporate sector for supporting
global programs with initial encouraging results [24,25].Health Research Policy and Systems 2004, 2:5 http://www.health-policy-systems.com/content/2/1/5
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Partnerships in the health sector can be for various pur-
poses; categories as stated by the Initiative on Public-Pri-
vate Partnerships for Health have been summarized in
Table 1. Such partnerships are novel arrangements and
potentially present an opportunity for more than one
partner(s) to contribute to the same goal. Many of these
have positively contributed to health outcomes in the
past; developing technologies for tropical diseases, sur-
veillance and screening strategies, contributing to techni-
cal aspects of sustainable drug development and vector
control are amongst a few examples [26,27]. Notwith-
standing, partnerships involving the for-profit private sec-
tor bring in their wake many concerns as they involve a
donor-recipient relationship [28].
In many countries, there are long established links of the
public sector with NGOs. Theoretically, since NGOs are
not driven by a profit generating motive, many of the eth-
ical challenges that potentially exist in partnering with the
for-profit are not of relevance in this case. However, it
could also plausibly be argued that NGOs, who though
objective and altruistic, may, in fact, have quite complex
motives. In promoting public-private partnerships there-
fore, several issues need to be clearly flagged in an attempt
to address them in tandem with efforts that aim to foster
such relationships. Within that context, a set of ethical
and process related challenges are summarized
hereunder:
Ethical challenges, which are largely generic across the range of 
public-private partnerships relate to the following dimensions
1. Global norms and principals: many of the large partner-
ships involving a variety of players are of a transnational
nature. However, against this backdrop, there are no glo-
bal norms and principals, to set a framework within
which global public health goals can be pursued in a part-
nership arrangement.
2. Impartiality in health: if public-private partnerships are
not carefully designed, there is a danger that they may reo-
rient the mission of the public sector, interfere with organ-
izational priorities, and weaken their capacity to uphold
norms and regulations. Such a shift is likely to displace the
focus from the marginalized and may therefore be in con-
flict with the fundamental concept of equity in health.
3. Social safety nets: it has been increasingly argued that
engaging in a partnership mode provides the public sector
an opportunity to renounce their responsibilities; this in a
sense may lead to withdrawal of social safety nets. Failure
to commit to maintain the role of the state in such part-
nerships may result in a laissez-faire attitude, prejudicial to
the interest of the most vulnerable groups.
4. Conflict of interest: many partnerships are initiated on
the premise that they fulfill a social obligation, and can
involve good intentions on part of individuals and
organizations. However the basic motive that drives the
'for-profit' sector demands that these involve a financial
pay off in the long term. In such cases, the difference
between corporate sponsorships and scientific philan-
thropic donations with long term visible public health
goals needs to be clearly separated. This issue has been
further complicated in recent years as many global health
initiatives funded by endowments generated by founda-
tions have partnerships with the private sector as a key fea-
ture [29]. Such donor-recipient relationships bring in
their wake many concerns. These include concerns relat-
ing to such arrangements providing the 'for profit' private
sector an opportunity to improve their organizational
image by engaging in cause-related marketing and con-
cerns relating to these engagements facilitating access of
the commercial sector to policy makers. On the other
hand, many NGOs even in the developing countries are
Table 1: Categorization of public-private partnerships based on the purpose they serve
Purpose Partnership
1 Product development GATBDD, IAVI, MMV and MVI.
2 Improving access to healthcare 
products
CF, MDP, Accelerated Access Initiative (AAI) [48], Global Alliance to Eliminate Leprosy (GAEL) [49], 
Global Alliance to Eliminate Lymphatic Filiariasis (GAELF) [50] and the Global Polio Eradication Initiative 
(GPEI) [51].
3 Global coordination mechanisms GAVI, RPS, Stop TB, Global Alliance for Improved Nutrition (GAIN) [52], and the Micronutrient Initiative 
(MI) [53].
4 Strengthening health services Alliance for Health Policy and Systems Research (AHPSR) [54], Multilateral Initiative on Malaria (MIM) 
[55], African Comprehensive HIV/AIDS Partnerships (ACHAP) [56].
5 Public advocacy and education Alliance for Microbicide Development (AMD) [57], African Malaria Partnership (AMP) [58], Global 
Business Coalition on HIV and AIDS (GBC) [59] and Corporate Council on Africa (CCA) [60].
6 Regulation and quality assurance The International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) [61], Pharmaceutical Security Institute (PSI) [62] and the Anti-
Counterfeit Drug Initiatives [63]Health Research Policy and Systems 2004, 2:5 http://www.health-policy-systems.com/content/2/1/5
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little more than lobby groups with a particular interest,
which may or may not be aligned to public good.
5. Redirecting national health polices: there are also concerns
that such partnerships redirect national and international
health polices and priorities and have the potential to
defeat crucial local and national efforts.
6. Fragmentation of the health system: partnerships generally
tend to aim for short term high profile goals and tend to
pick the lowest lying fruits. Partnerships do have the man-
date and cannot be held accountable to synchronize their
activities with emerging processes within countries aimed
at developing their health systems. Therefore if they are
instituted in countries with weak health systems they have
the potential to fragment the healthcare system by insti-
tuting independent vertical programs. The changing glo-
bal agenda around 'vaccines' helps to highlight many of
these issues. Previously polices around vaccination were
grounded in the general principal that promoted equita-
ble access to few vaccines around the world. However new
initiatives and their vertical systems have less of a focus on
sustainability, may not contribute to strengthening of the
health system and have the potential of redirecting
national health policies, which focus on equitable care
[30].
7. Contribution to common goals and objectives: it is common
for partners to have different objectives while pursuing a
relationship though it may be implicit that partnerships
are contributing to common goals.
8. Lack of outcome orientation: many a times, partnerships
exist in form and do not contribute to improvements in
quality and efficiency.
Operational and process-related challenges in public private 
partnerships relate to the following dimensions
1. Legislative frameworks, polices and operational strategies:
many developed countries have legislation to interface
with the private sector [31]. However in the developing
world, there is a general failure, to have overarching legis-
lation relating to public-private partnerships. As a result,
such arrangements develop on an ad hoc and opportunis-
tic basis and may have questionable credibility; as a
results of this failure, polices and specific operational
strategies fail to develop.
2. Participatory approach to decision making: the expression
'partnership' gives the impression of equality. However
many a times, a participatory approach to the decision
making process is usually not optimally accomplished.
This has implications of varying degrees. Almost all the
large 91 transnational partnerships referred to earlier are
focused on the developing world. However, among these,
85 have their secretariats in Europe and North America;
the United States and Switzerland being the commonest
host countries. Cleary this lack of proximity to the
intended beneficiaries has a bearing on the manner in
which the beneficiaries have a role in the decision making
process [32]. The decision-making process in a partner-
ship may also be biased because of the stronger partners'
influence. At a county level and in the case of govern-
ments interfacing with NGOs, the stronger partner, which
his usually the Government generally tends to make the
rules. On the other hand, in the case of relationships with
the 'for-profit' private sector, there is the danger of the
financially stronger partner influencing the public sectors
decision making process on policies, regulatory and legis-
lative matters, which have implications for their profit-
making motive.
3. Governance structures: workable partnerships require a
well-defined governance structure to be established to
allow for distribution of responsibilities to all the players.
Public-private partnerships may run into problems
because of ill-defined governance mechanisms. Recent
evaluation of the RBM project while acknowledging the
successes of the partnership in drawing global attention to
the scale of the problem posed by Malaria has outlined
serious governance-related issues [33]. More recently,
independent evaluation of the Global Stop TB partnership
has also resulted in the issuance of detailed recommenda-
tions for improved governance [34].
4. Power Relationships: skewed power relationships are a
major impediment to the development of successful rela-
tionships. Governments in developing countries usually
tend to assume core responsibility of the joint initiative
and take charge of the weaker partner. In case of NGOs
with outreach-related strengths, this usually takes the
form of a 'contractual relationship' without much regard
to the participatory processes, which should be key to a
public-private partnership arrangement. In case of rela-
tionships with NGOs with technical strength, there are
issues relating to power relationships of a more serious
nature with regard to who assumes the leadership role.
9. Criteria for selection: the criteria for selection are an
important issue both from an ethical and process-related
perspective as it raises the questions of competence and
appropriateness. In many instances the public sector is
vague about important issues related to screening poten-
tial corporate partners and those in the non-profit sector.
10. Sustainability: the question of long-term sustainability
is often ignored in public-private partnerships. An analy-
sis of the operation of GAVI has concluded that it overem-
phasizes high technology vaccines, lacks sustainability,
relies too heavily on the private sector and consequently,Health Research Policy and Systems 2004, 2:5 http://www.health-policy-systems.com/content/2/1/5
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runs the risk of compounding health inequities in the
poorest countries [35].
11. Accountability: many partnerships do not ensure that
all players are held accountable for the delivery of effi-
cient, effective and equitable services in a partnership
arrangement. Often in public-private relationships it is
unclear as to whom are these partnerships accountable to,
according to what criteria, and who sets priorities? To
hold partners accountable for their actions, it is impera-
tive to have clear governance mechanisms and clarify part-
ner's rights and obligations. Clarity in such relationships
is needed in order to avoid ambiguities that lead to break
up of partnerships. A case in point is the recent breakup of
GAEL with the exit of the International Association of
Anti-leprosy [36].
The Call to Action
In the world we live today, global agendas are being
increasingly shaped by the private sector. The 'for-profit'
private sectors' immense resources make it an irresistible
partner for public health initiatives. These arrangements
can also be mutually synergistic. Governments and inter-
national agencies can tap into additional resources to full
fill their mandate whereas the commercial sector can ful-
fill its social responsibility, for which it is being increas-
ingly challenged. Additionally, the recent SARS epidemic
and bio-terrorist threats should help to make the private
sector understand the value of investment in health for
reasons beyond fulfilling their social obligations. Active
involvement of the 'non-profit' sector and donor coordi-
nation in country goals is also being increasingly encour-
aged within comprehensive development frameworks;
this approach is synchronous and in harmony with the
Poverty Reduction Strategy Paper Framework [37].
The development and health actors have highlighted the
need to harness the potential that exists in collaborating
with the private sector to advance public health goals. This
is also becoming increasingly essential as both the public
and the private sector recognize their individual inabilities
to address emerging public health issues that continue to
be tabled on the international and within country policy
agendas. Public-private partnerships therefore seem both,
unavoidable and imperative. However in building such
collaborations, certain measures must be taken at a global
level to assist global partnerships and set a framework
within which efforts at a country level can emanate.
As a first step, there is a need to develop a set of global
norms and ethical principles; a broad-based agreement
over these must be achieved. The transnational nature and
global outlook of emerging partnerships necessitate that
these stem from a broad-based international dialogue.
It is critical that the driving principles for such initiatives
be rooted in 'benefit to the society' rather than 'mutual
benefit to the partners' and should center on the concept
of equity in health. Norms must stipulate that partner-
ships contribute to strengthening of social safety nets in
disadvantaged settings and should be set within the con-
text of 'social responsibility' as the idea is not meant for
private funds to be put to public use nor to privatize pub-
lic responsibilities.
Global principles must specify that partnerships should
be in harmony with national health priorities; they
should complement and not duplicate state initiatives
and should be optimally integrated with national health
systems without any conflict of interest. Norms must
make it mandatory for all partners in a 'partnership'
arrangement to contribute to common goals as a true part-
nership is one in which the partners, though having differ-
ent motivation and values have a shared objective. Global
norms must outline that partners be committed to mak-
ing contributions, sharing risks and the decision making
process. Principles should emphasize an outcome orienta-
tion. Development of a public-private partnership in itself
should not be seen as an outcome, but a process and an out-
put; it is important for partnerships not to just exist in
form but to contribute to improvements in health
outcomes.
It must be made binding for international agencies to
develop transparent policy and procedural frameworks.
Many international agencies have established guidelines
on interacting with the private sector [38-45]. However
there is a need for comprehensive polices and operational
strategies, which are crucial to ensuring transparency and
protecting public interest [46]. Inviting third party reviews
and ensuring an open process for deliberations will help
to ensure transparency and reflect that these processes are
indeed being structured in public interest.
Global efforts should demand, encourage and assist the
development of policy and legislative frameworks shap-
ing public-private partnerships within  countries [47].
However in the setting of developing countries, there is a
need for international actors to guide these and for them
to emanate within the framework of global norms and
standards. Assisting with capacity development through
donor coordination may be a necessary prerequisite to
this approach. Legislative and policy frameworks within
countries will help to legitimize public-private relation-
ships, lend credence to this approach, help to foster an
enabling environment and provide a mandate for the
development of ethical guidelines to further direct these
initiatives.Health Research Policy and Systems 2004, 2:5 http://www.health-policy-systems.com/content/2/1/5
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Within stipulated legislative and policy frameworks, sup-
port must be provided to developing countries to develop
specific guidelines to steer such relationships. Guidelines
can assist with the development of selection criteria and
help specify roles of the public and the private sectors.
They can also assist with the development of models that
outline combined governance structures, clearly aimed at
improved systems of governance. Guidelines must also
articulate a clear policy on a participatory approach to the
decision making process. In addition, they should assist
with assigning responsibilities to various levels of Govern-
ment and then hold people and institutions both within
Governments and those in the private sector that partner
with them accountable for their performance.
Though an evidence-based approach and ethical consider-
ations must never be compromised in such endeavors and
every effort should be made to ensure that goals are mutu-
ally compatible, guidelines also need to be flexible in
order to accommodate each partner's organizational
requirements and integrity. Moreover they need to be
pragmatic. The public sector needs to recognize the basic
legitimacy of the private sector and the profit motive that
drives it. It is also essential for the public sector to respect
the organizational autonomy and priorities of the non-
profit sector. In this context, partnerships and contractual
relationships need to be carefully differentiated.
Partnerships must also be the subject of noteworthy
empirical research, which would enable a detailed assess-
ment of the specific issues inherent to the various types of
public-private partnership arrangements from an ethical
and methodological perspective.
The impetus for driving global and national efforts in cre-
ating a transparent and conducive environment for pub-
lic-private partnerships needs to come from the public
sector. This raises the issue of capacity within countries;
the gap needs to be bridged by assistance from UN agen-
cies, which have the mandate of harnessing and coordi-
nating support among a variety of players for global
actions. However, the results of such actions will only be
as good as Governments make them; weak and poorly
informed Governments cannot remedy their own defi-
ciencies by seeking to yolk the private sector to their own
uncertain cart.
In conceptualizing a framework that assists with setting
global norms and guidelines and within-country legisla-
tive actions, it needs to be recognized that the dynamics of
public-private partnership arrangements are generic
across social sector. It may therefore be useful to allow this
commonality to prevail in initiating global and country-
specific actions.
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